Greenlane Holdings, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The report was signed July 18, 2024. The filing provides annual results, not a clear standalone fourth-quarter income statement; the figures below are for the full year unless stated otherwise.
Business context
Greenlane distributes cannabis accessories, vaporizers, packaging and lifestyle products through wholesale, retail and e-commerce channels. It reports Consumer Goods and Industrial Goods segments. During 2023, it shifted much of certain Industrial Goods sales to an agency commission model, discontinued its packaging inventory business and prioritized cost reductions, working-capital conservation and higher-margin owned brands.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Net sales | $65.4 million | $137.1 million |
| Gross profit / gross margin | $17.8 million / 27.3% | $25.0 million / 22.3% |
| Operating loss | $26.1 million | $184.1 million |
| Net loss | $32.3 million | $182.2 million |
| Net loss attributable to Greenlane | $32.2 million | $169.5 million |
| Interest expense | $5.5 million | $2.5 million |
| Cash used in operating activities | $1.8 million | $26.4 million |
At December 31, 2023, cash was $0.5 million, working capital was approximately $3.7 million, current assets were $29.8 million and current liabilities were $26.1 million. Notes payable totaled $7.3 million, all classified as current; operating lease liabilities were approximately $1.9 million. The filing says available cash and expected operating cash flow were insufficient for the next 12 months and could fund planned operations only into the third quarter of 2024. The auditor highlighted substantial doubt about the Company’s ability to continue as a going concern.
Changes versus 2022
- Revenue fell 52.3%. Management attributed much of the decline to the Industrial segment’s transition from recording gross product sales to commission revenue and to exiting packaging inventory sales; Consumer Goods also weakened amid restructuring, reduced sales and marketing spending, and inventory constraints.
- Gross margin rose five percentage points to 27.3%, reflecting commission revenue recorded at 100% margin and a greater focus on higher-margin products. Gross profit nevertheless declined 28.6%.
- Operating expenses fell to $43.9 million from $209.1 million. The 2022 comparison included $129.4 million of goodwill, intangible-asset and property-and-equipment impairments; no comparable impairment charge was recorded in 2023.
- Consumer Goods sales decreased 40.3% to $28.7 million; segment gross margin increased to 34.7% from 20.0%. Industrial Goods sales decreased 58.8% to $36.6 million; segment gross margin increased to 21.4% from 17.3%.
- Cash used in operations improved to $1.8 million, helped substantially by reductions in inventory, receivables and vendor deposits. Cash declined from $6.5 million at year-end 2022 to $0.5 million at year-end 2023.
Outlook, management actions and key risks
- Management did not provide formal numerical revenue or earnings guidance. Its stated goal is near-term profitability, supported by further cost reductions, new products and customer acquisition, strategic partnerships, and additional debt or equity financing.
- The Company reduced headcount by approximately 49% during 2023 and cited expected annualized cash compensation savings of approximately $10 million. It also consolidated facilities and expects the full benefit of footprint reductions to be realized in 2024.
- April 2023 partnerships for packaging and vaporizer customers are intended to reduce inventory and working-capital needs and improve margins, but may reduce reported top-line revenue. In May 2024, Synergy purchased specified Eyce and DaVinci brand assets; the related secured note was modified and its maturity extended through July 2024.
- Financing included approximately $3.9 million net proceeds from the July 2023 equity offering and approximately $3.9 million from future-receivables financings. The Company repaid its $15 million asset-based loan in 2023, but year-end debt included current receivables financing and a secured bridge loan. Additional capital may be needed; equity financing could be dilutive.
- Key risks include continued losses and very limited cash, supplier and customer concentration, narrow margins, shipping restrictions, evolving cannabis and vaporizer regulation, possible Nasdaq delisting, and execution risks from restructuring and the ERP system. One customer generated approximately 21% of 2023 net sales; CCELL-manufactured products represented approximately 41.5% of net sales.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to material weaknesses, including deficiencies in IT access, risk assessment, journal-entry review and monitoring. The 10-K also reports late-filing-related Nasdaq noncompliance notices and a separate minimum-bid-price deficiency.
- The financial statements received an unqualified audit opinion, but the auditor’s report emphasized the going-concern uncertainty. Management reported no litigation reserves at year-end and did not believe pending proceedings would have a material adverse effect; outcomes remain uncertain.
Most important facts for investors to verify
- Current liquidity, cash burn and the status of financing, debt repayments and the July 2024 loan maturity after the reporting date.
- Whether cost reductions and partnerships produce sustainable positive operating cash flow, and how commission-model changes affect comparable revenue and margins.
- Progress in remediating material weaknesses, timely filing required reports and maintaining Nasdaq listing compliance.
- Potential dilution from outstanding warrants and subsequent share issuance: the filing says 1,911,000 pre-funded-warrant shares were issued after year-end; confirm current shares outstanding and remaining warrant exposure.
- Exposure to major suppliers and customers, regulatory or shipping changes, and any material developments in legal, tax or other contingencies.